Insulet (PODD)
(Delayed Data from NSDQ)
$204.42 USD
+11.84 (6.15%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $202.65 -1.77 (-0.87%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$204.42 USD
+11.84 (6.15%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $202.65 -1.77 (-0.87%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum C VGM
Zacks News
Insulet's Omnipod 5 Wins FDA Approval for Type 2 Diabetes
by Zacks Equity Research
PODD marks a major milestone with Omnipod 5 approval for the treatment of type 2 diabetes.
Illumina (ILMN) Beats on Q2 Earnings, Lowers 2024 Sales View
by Zacks Equity Research
Illumina's (ILMN) Q2 earnings and revenues surpass estimates in a challenging global macroeconomic environment.
Insulet (PODD) Q2 Earnings Miss Estimates, '24 Sales View Raised
by Zacks Equity Research
Insulet's (PODD) second-quarter performance benefits from the continued high demand for Omnipod 5.
Insulet (PODD) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Insulet (PODD) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Insulet (PODD) Q2 Earnings Miss Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of -3.51% and 5.48%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Unlocking Q2 Potential of Insulet (PODD): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Insulet (PODD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Insulet (PODD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EYE vs. PODD: Which Stock Is the Better Value Option?
by Zacks Equity Research
EYE vs. PODD: Which Stock Is the Better Value Option?
Boston Scientific (BSX) Q2 Earnings Beat, Organic Sales Rise
by Zacks Equity Research
Boston Scientific (BSX) registers a strong year-over-year improvement in sales, indicating solid market share gains in legacy businesses across all geographic regions.
Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2024 EPS View
by Zacks Equity Research
The year-over-year decline in Thermo Fisher's (TMO) Life Science Solutions and Laboratory Products and Biopharma Services revenues disappoints. However, margins expand in the second quarter.
All You Need to Know About Insulet (PODD) Rating Upgrade to Strong Buy
by Zacks Equity Research
Insulet (PODD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Abbott (ABT) Q2 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
Abbott (ABT) delivers a strong underlying base business performance in the second quarter of 2024.
ESLOY vs. PODD: Which Stock Is the Better Value Option?
by Zacks Equity Research
ESLOY vs. PODD: Which Stock Is the Better Value Option?
Insulet's (PODD) Omnipod 5 Favored in Study for Type 2 Diabetes
by Zacks Equity Research
Insulet (PODD) reports positive findings from the SECURE-T2D pivotal trial, the largest study of AID therapy in people with type 2 diabetes.
Insulet (PODD) Unveils Key Achievements for the Omnipod 5 System
by Zacks Equity Research
Insulet (PODD) debuts the Omnipod 5 AID system in France and announces new updates for the U.S. markets.
Is Insulet (PODD) Stock an Apt Pick for Your Portfolio Now?
by Zacks Equity Research
The robust performance of Insulet's (PODD) Omnipod 5 raises investors' optimism. However, concerns remain over the macroeconomic impacts and the company's overdependence on a single platform.
Here's Why Insulet (PODD) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Insulet (PODD) Q1 Earnings Top, 2024 Revenue View Raised
by Zacks Equity Research
Insulet's (PODD) first-quarter performance benefits from the continued high demand for Omnipod 5.
Here's What Key Metrics Tell Us About Insulet (PODD) Q1 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Gear Up for Insulet (PODD) Q1 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Insulet (PODD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Insulet (PODD) Rises Higher Than Market: Key Facts
by Zacks Equity Research
In the most recent trading session, Insulet (PODD) closed at $173.42, indicating a +1.85% shift from the previous trading day.
Why Insulet (PODD) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.